De novo design of miniprotein-based natural killer cell engagers

แชร์
ฝัง
  • เผยแพร่เมื่อ 9 ก.พ. 2025
  • Presented on December 11th 2024 by Mireia Solà Colom
    Abstract:
    Immune cell engagers are a promising modality for cancer therapy, but many limitations must still be overcome before this approach will reach its full potential. De novo-designed miniproteins allow engineering high-valency immune cell engagers equipped with any imaginable functionality while allowing sophisticated control over on-cell binding, immune cell activation and immune synapse formation.

ความคิดเห็น •